-
1.
公开(公告)号:US09879231B2
公开(公告)日:2018-01-30
申请号:US14837382
申请日:2015-08-27
申请人: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
发明人: Bernard Moss , Linda S. Wyatt , Patricia L. Earl
IPC分类号: C12N7/00 , C07K14/005 , C12N15/86 , C12N15/863 , A61K39/285 , A61K39/00
CPC分类号: C12N7/00 , A61K39/285 , A61K2039/5256 , C07K14/005 , C12N15/86 , C12N15/8636 , C12N2710/24121 , C12N2710/24133 , C12N2710/24143 , C12N2710/24152 , C12N2740/16122 , C12N2740/16222
摘要: The present invention relates to recombinant modified vaccinia Ankara (MVA) virus containing restructured sites useful for the integration of heterologous nucleic acid sequences into an intergenic region (IGR) of the virus genome, where the IGR is located between two adjacent, essential open reading frames (ORFs) of the vaccinia virus genome, wherein the adjacent essential ORFs are non-adjacent in a parental MVA virus used to construct the recombinant MVA virus, and to related nucleic acid constructs useful for inserting heterologous DNA into the genome of a vaccinia virus, and further to the use of the disclosed viruses as a medicine or vaccine.
-
公开(公告)号:US09708392B2
公开(公告)日:2017-07-18
申请号:US14663168
申请日:2015-03-19
申请人: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
IPC分类号: C07K14/005 , C07K16/08 , G01N33/569 , A61K39/00
CPC分类号: C07K16/081 , A61K39/00 , A61K2039/505 , A61K2039/545 , C07K14/005 , C07K2317/21 , C07K2317/24 , C07K2317/51 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N2710/24122 , G01N33/56983 , G01N2333/07
摘要: The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
-